FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI® in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and […]

Read More… from FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS ON MARCH 21, 2024

March 19, 2024 RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and […]

Read More… from FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS ON MARCH 21, 2024

FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND

March 17, 2024 Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory […]

Read More… from FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND

FENNEC PHARMACEUTICALS REPORTS PRELIMINARY UNAUDITED NET REVENUE FOR FOURTH QUARTER AND FULL-YEAR 2023 RESULTS

February 29, 2024~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty […]

Read More… from FENNEC PHARMACEUTICALS REPORTS PRELIMINARY UNAUDITED NET REVENUE FOR FOURTH QUARTER AND FULL-YEAR 2023 RESULTS

FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT FROM PETRICHOR

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK®Which Occurred on September 20, 2022 ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT FROM PETRICHOR

FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ Research Triangle Park, NC, August 22, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]

Read More… from FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR

FENNEC PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF PEDMARK® (SODIUM THIOSULFATE INJECTION)

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF PEDMARK® (SODIUM THIOSULFATE INJECTION)

FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action DateSet for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Commercialization of PEDMARKTM ~ Research Triangle Park, NC, August […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ~ Funding to Support the Potential Commercialization of PEDMARKTM to Reduce the […]

Read More… from Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) –June 14, 2022 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]

Read More… from Fennec Announces Results of Annual Meeting